Glycobiology Market to Surpass US$ 4,153.76 Mn by 2030

Global Glycobiology Market, by Product Type (Instruments, Enzymes, Consumables, Reagents & Kits, and Others), by Application (Diagnostic Applications, Industrial Applications, Therapeutic Applications, Drug Discovery and Development, and Others), by End User (Research Laboratories, Hospitals, Diagnostic Centers, Biopharmaceutical Companies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,568.73 Million in 2022 and is expected to exhibit a CAGR of 12.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Glycobiology market is expected to gain significant traction, owing to the applications of glycobiology enzymes, instruments, and other tools in cancer research and treatment. Recent advancements in glycobiology techniques to enhance the accuracy of treatment with the approval from regulatory agencies is a major factor augmenting growth of the glycobiology market. For instance, in July, 2022, American Society for Biochemistry and Molecular Biology held a conference on O-GlcNAc regulation of cellular physiology and pathophysiology. The several functions of O-GlcNAc protein modification in controlling nuclear and cytosolic proteins were discussed at this conference. It brought together the researchers from various sectors to exchange knowledge, resources, and experience in O-GlcNAc biology, to explore how O-GlcNAc and O-GlcNAc cycling enzymes regulate protein function in both normal biological processes and disease states like diabetes, cancer, cardiovascular disease, and neurological illnesses.

Global Glycobiology Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in December 2019, as ‘coronavirus disease 2019’, or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and global health in the world.

 The COVID 19 had positive impact on glycobiology market, due to its application in production of antiviral vaccines. Most of the glycans were utilized for antiviral vaccine production and production of antibodies, which can be expected to drive the glycobiology market growth. For instance, in February 2021, Journal of Biological Chemistry, published a paper on how glycobiology can help to treat the COVID-19 infection. Glycobiological contributions of  COVID-19 therapeutic candidates, including vaccine glycans, anti-glycan antibodies, recombinant lectins, lectin inhibitors, glycosidase inhibitors, polysaccharides, and multiple glycosides, highlight opportunities for repurposing U.S. FDA-approved drugs to Biotechnological engineering of new probes to prevent the SARS-CoV-2 infection may be based on the crucial glycobiological understanding of glycosyltransferases, glycans, glycan-binding proteins, and glycosidases connected to this pathology for the next-generation medications.

Global Glycobiology Market: Key Developments

In March 2020, Ludger, a company specializing in glycomics and carbohydrate analysis technologies, supporting biopharmaceutical delivery and translational medicine, launched a new product Exoglycosidase. Exoglycosidase is used to assist in the structural characterization of glycans.

According to an article published by Frontiers Media in May 2022, the researchers in Cellular and Molecular Biotechnology Research Institute had launched glycobiology in single cell and microbiomes by sequencing of glycan profiling. This technique enables simultaneous analysis of glycans and RNA (ribonucleic acid) in a single cell. Based on this concept, reserchers developed a technique called scGR-seq to analyze sugar chains and RNA in single cells. Glycan and gene expression profiles of individual cells comprising heterogeneous cell populations such as tissues were obtained using scGR-seq.

Browse 36 Market Data Tables and 38 Figures spread through 252 Pages and in-depth TOC on “Global Glycobiology Market”-  Forecast to 2030, by Product Type (Instruments, Enzymes, Consumables, Reagents & Kits, and Others) by Application ( Diagnostic Applications, Industrial Applications, Therapeutic Applications, Drug Discovery and Development, and Others), by End User (Research Laboratories, Hospitals, Diagnostic Centers, Biopharmaceutical Companies, and Others) , and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/glycobiology-market-3639

Key Takeaways of the Global Glycobiology Market:

• Global glycobiology market is expected to exhibit a CAGR of 12.9% during the forecast period due to the increasing applications of glycobiology such as its role as building block of life. For instance, in March, 2023, the following year, the Gordon Research Conferences announced a conference on the biological role of glycan as key building blocks of life.
• Among end users, the Biopharmaceuticals companies segment is estimated to hold a dominant position in the global glycobiology market over the forecast period, owing to increased product launch by key players in the market. For instance, in October 2020, S-BIO a company providing glycan solutions, had launched EZGlyco O-glycan kit that can be used for quick and reliable O-glycan analysis.
• On the basis of regions, North America is estimated to account for the largest market share in the global glycobiology market over the forecast period, owing to increasing innovations such as new drug discovery and product launches by the key players. For instance, in April, 2022, Bruker Corporation, a manufacturer of scientific instruments for molecular and materials research, launchedew MALDI HiPLEX-IHC tissue imaging solution for timsTOF fleX that uses AmberGen's HiPLEX-IHC peptide-encoding antibody probes in combination with unbiased lipidomics, glycomics, and metabolomics tissue imaging.
• Major players operating in the global glycobiology market includes Tracxn Technologies Limited, Agilent Tecnologies,Inc., Blirt.eu, Takara Bio Inc., Bio-Techne, Bruker Corporation, Thermo Fisher Scientific Inc., Shimadzu Corporation, New England Biolabs., Waters.co., Merck KGaA, Palleon Pharmaceuticals, Asparia Glycomics, RayBiotech Life,Inc., Z Biotech,LLC., Chemily Glycoscience,  Lectenz Bio, 2BScientific, and Glycodiag